Perspective Therapeutics doses first patient in Phase 1/2a trial of PSV359 for FAP-α positive solid tumors

Perspective Therapeutics, Inc.

First patient dosed with [212Pb]PSV359 in Phase 1/2a dose-finding trial for FAP-α positive solid tumors.
Patients selected via SPECT imaging with [203Pb]PSV359 to identify FAP-α expression.
Trial aims to determine safety and preliminary anti-tumor activity; dose selection for monotherapy or combination.
PSV359 construct optimized for tumor uptake, retention, and fast clearance from healthy tissues.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.